The Food and Drug Administration today alerted health care providers to safety risks associated with cesium chloride, a mineral salt sometimes taken by cancer patients who seek alternative treatments. Reported adverse events included QT prolongation (a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm), low potassium, seizures, potentially lethal arrhythmias, fainting, cardiac arrest and death. FDA also said it intends to move cesium chloride to the category of substances that present significant safety risks in compounding.
Learn how a Patient Risk Assessment Profile allowed nurses to proactively assess patient risk to guide staffing decisions and nurse-patient assignment.…
Tuesday, August 6, 2019
AHA encourages Congressional leaders to pass the Pandemic and All-Hazards Preparedness…
How are value and health equity connected?
Download the letter (PDF) below Re: CMS—3346—P, Medicare
In 2001, a Samaritan Health Services (SHS) physician, Dr. Richard Wopat, recognized the need to improve birth outcomes of high-risk pregnant women in the…